Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the management of acute and chronic graft versus host disease (GvHD). In the acute GvHD field, ruxolitinib is an effective treatment option for patients with steroid-refractory acute GvHD. Prof. Mohty goes on to discuss the treatment options for chronic GvHD. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).